Alejandra Reolid

Alejandra Reolid

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MLMar Llamas-Velasco
Mar Llamas-Velasco
PMP. Muñoz‐Hernández
P. Muñoz‐Hernández
JLJ. Lázaro‐González
J. Lázaro‐González
ARAlejandra Reolid
Alejandra Reolid
BAB. Abad‐Santamaría
B. Abad‐Santamaría
EDEsteban Dauden
Esteban Dauden

4 June 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
ARA. Reymundo
A. Reymundo
AFA. Fernáldez‐Bernáldez
A. Fernáldez‐Bernáldez
ARAlejandra Reolid
Alejandra Reolid
BBB. Butrón
B. Butrón
PFP. Fernández‐Rico
P. Fernández‐Rico
MLMar Llamas-Velasco
Mar Llamas-Velasco

20 December 2020 in Medicina
Verified
Journal Article
Open access
PDF file
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
LMLuisa Martos-Cabrera
Luisa Martos-Cabrera
MOMaría Carmen Ovejero-Benito
María Carmen Ovejero-Benito
ARAlejandra Reolid
Alejandra Reolid
Francisco Abad-SantosFrancisco Abad-Santos
Francisco Abad-Santos
EDEsteban Dauden
Esteban Dauden
Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response. Materials and Methods: In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs. Results: Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele. Conclusions: Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.

11 February 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MOMaría Carmen Ovejero-Benito
María Carmen Ovejero-Benito
EME. Muñoz‐Aceituno
E. Muñoz‐Aceituno
DSD. Sabador
D. Sabador
ARAlejandra Reolid
Alejandra Reolid
MLMar Llamas-Velasco
Mar Llamas-Velasco
EDEsteban Dauden
Esteban Dauden

12 October 2019 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ARAlejandra Reolid
Alejandra Reolid
EMEster Muñoz‐Aceituno
Ester Muñoz‐Aceituno
PJPedro Rodriguez Jimenez
Pedro Rodriguez Jimenez
EGEsperanza González‐Rojano
Esperanza González‐Rojano
MLMar Llamas-Velasco
Mar Llamas-Velasco
EDEsteban Daudén
Esteban Daudén

1 March 2021 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
ARAlejandra Reolid
Alejandra Reolid
EME. Muñoz-Aceituno
E. Muñoz-Aceituno
FAF. Abad-Santos
F. Abad-Santos
MOM. C. Ovejero-Benito
M. C. Ovejero-Benito
EDE. Daudén
E. Daudén